Page 18 - INFO junho 2017

INFO Junho2017 Terapêutica Médica

BIBLIOGRAFIA
1. Fong ZV, Tanabe KK. The clinical manage- 11. Verslype C, Rosmorduc O, Rougier P; ESMO
ment of hepatocellular carcinoma in the United Guidelines Working Group. Hepatocellular carci-
States, Europe and Asia: comprehensive and noma: ESMO-ESDO Clinical Practice Guidelines
evidence-based comparison and review. Can- for diagnosis, treatment and follow-up. Ann On-
cer. 2014;120(18):2824-38. col. 2010; 21(Suppl. 5):v59-v64.
2. Fatourou EM, Tsochatzis EA. ART and science 12. Lencioni R, Kudo M, Ye SL, et al. GIDEON
in using transarterial chemoembolization for re- (Global Investigation of therapeutic DEcisions in
treating patients with hepatocellular carcinoma. hepatocellular carcinoma and Of its treatment
Hepatobiliary Surg Nutr. 2014;3(6):415-18. with sorafeNib): second interim analysis. Int J
Clin Pract. 2014;68(5):609-17.
3. Llovet JM, Fuster J, Bruix J; Barcenola-Clínic
Liver Cancer Group. The Barcelona Approach: 13. Louaf S, Boige V, Ducreux M, et al. Gemci-
diagnosis, staging, and treatment of hepato- tabine plus oxaliplatin (GEMOX) in patients with
cellular carcinoma. Liver Transpl. 2004; 10(2 advanced hepatocellular carcinoma (HCC). Can-
Suppl 1):S115-20. cer. 2007;109(7):1384-90.
4. Sieghart W, Hucke F, Pinter M, et al. The 14. Boige V, Raoul JL, Pignon JP, et al. Multicen-
ART of decision making: retreatment with tre phase II trial of capecitabine plus oxaliplatin
transarterial chemoembolization in patients (XELOX) in patients with advanced hepatocellu-
with hepatocellular carcinoma. Hepatology. lar carcinoma: FFCD 03-03 trial. Br J Cancer.
2013;57(6):2261-73. 2007;97:862-7.
5. Hucke F, Sieghart W, Pinter M, et al. The ART- 15. Patt YZ, Hassan MM, Aguayo A, et al. Oral
strategy: Sequential assessment of the ART capecitabine for the treatment of hepatocellular
score predicts outcome of patients with hepato- carcinoma, cholangiocarcinoma, and gallblad-
cellular carcinoma re-treated with TACE. J Hepa- der carcinoma. Cancer. 2004;101:578-86.
tol. 2014;60(1):118-26.
16. Gish RG, Porta C, Lazar L, et al. Phase III
6. Sousa IJ, Rodrigues J, Pais A, Bonito N, et al. randomized controlled trial comparing the survi-
Hepatocellular carcinoma (HCC): ART-score and val of patients with unresectable hepatocellular
retreatment with transarterial chemoemboli- carcinoma treated with nolatrexed or doxorubi-
zation (TACE). The European Cancer Congress. cin. J Clin Oncol. 2007;25(21):3069-75.
2015. Abstract number 2263.
17. Yang TS, Lin YC, Chen JS, et al. Phase II study
7. Hickey RM, Lewandowski RJ, Salem R. Yt- of gemcitabine in patients with advanced hepato-
trium-90 radioembolization for hepatocellu- cellular carcinoma. Cancer. 2000;89(4):750-6.
lar carcinoma. Seminars Nuclear Medicine. 18. Parikh PM, Fuloria J, Babu G, et al. A phase
2016;46:105-8.
II study of gemcitabine and cisplatin in patients
8. Mosconi C, Cappelli A, Pettinato C, Golferi R. with advanced hepatocellular carcinoma. Trop
Radioembolization with Yttrium-90 microsphe- Gastroenterol. 2005;26(3):115-8.
res in hepatocellular carcinoma: Role and pers- 19. Bruix J, Merle P, Granito A, et al. LBA-03 Eff-
pectives. World J Hepatol. 2015;7: 738-52.
cacy and safety of regorafenib versus placebo in
9. National Comprehensive Cancer Network patients with hepatocellular carcinoma progres-
(NCCN). NCCN Clinical Practice Guidelines in On- sing on sorafenib: Results of the international,
cology: Hepatobiliary Cancers. Version 2.2016. randomized phase 3 RESORCE trial. Annals of
Fort Washington, PA: NCCN.2016. Oncology. 2016;27:(Supp. 2):ii1-ii3.
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sora- 20. Lencioni R, Llovet JM. Modifed RECIST
fenib in advanced hepatocellular carcinoma. N (mRECIST) asessment for hepatocellular Carci-
Engl J Med. 2008. 359(4):378-90. noma. Semin Liver Dis. 2010; 30(1):52-60.

18